Fig. 1: Bisthianostat (BIS) induces dose-dependent cytotoxicity in MM cells. | Acta Pharmacologica Sinica

Fig. 1: Bisthianostat (BIS) induces dose-dependent cytotoxicity in MM cells.

From: Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma

Fig. 1

a RPMI-8226 cells were cultured with control medium or BIS (0–3 μM) or SAHA (0–3 μM) for 20 h. Whole-cell lysates were subjected to Western blotting for the change of acetylated α-tubulin and H3. b RPMI-8226 cells were cultured with control medium or 3 μM BIS or SAHA for different time. Whole-cell lysates were subjected to Western blotting for the change of acetylated α-tubulin and PARP cleavage. c RPMI-8226 cells were treated with BIS (0–10 μM) or SAHA (0–10 μM) for 48 h. Cell apoptosis was evaluated with Annexin V/PI FACS assay. d Seven MM cell lines were treated with increasing doses of BIS or SAHA for 72 h, and cell viability was measured by CCK8 assay, and the IC50 was calculated with GraphPad.

Back to article page